• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » etrials Cuts Costs—and Losses in Q1

etrials Cuts Costs—and Losses in Q1

May 13, 2009
CenterWatch Staff

eClinical vendor etrials Worldwide cut its net loss for the first quarter 2009 in half from the same period 2008 by reducing operating expenses, the company said. Net loss for Q1 was $960,000, compared with $2 million in Q1 2008—and $5.5 million in the fourth quarter 2008.

Net service revenues for the first quarter 2009 held steady at $3.6 million, compared with $3.7 million for the first quarter 2008.

New project bookings for the quarter fell to $1.9 million compared with $4.8 million in the same period last year. The company experienced cancellations of $5 million in the first quarter—“a direct reflection of the volatile economic times,” said a company release.

"etrials first quarter performance was disappointing in terms of awards and cancellations, but reassuring in terms of our cost management efforts, customer-centric culture and ability to renew and deepen customer relationships," said etrials president and CEO M. Denis Connaghan.

This may be the last earnings release for etrials as an independent company. The Morrisville, N.C.-based company has entered into an acquisition agreement with BioClinica (formerly Bio-Imaging) that is expected to close in June. As a result of this pending deal, etrials did not hold an investor conference call to report its first quarter earnings.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing